Radiopharmaceuticals – our new study reveals trends, R&D progress, and predicted revenues Where is the Radiopharmaceutical market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead Our 234-page report provides 193 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 6 Applications, 11 Radioisotopes, 2 Sources, and 4 end-users
Radiopharmaceuticals, by Source • Cyclotrons • Nuclear Reactors
Radiopharmaceuticals, by End User • Hospitals • Diagnostic Imaging Centres • Ambulatory Surgical Centres • Cancer Research Institutes
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets: • North America: • The US • Canada • Latin America: • Brazil • Mexico • Rest of Latin America
• Western Europe: • Germany • UK • Italy • Spain • France • Nordic Countries • Benelux • Rest of Western Europe
• Eastern Europe: • Russia • Poland • Rest of Eastern Europe
• APAC: • Japan • China • India • Australia & New Zealand • ASEAN countries • Rest of Asia-Pacific
• MEA: • South Africa • GCC • North African countries • Rest of MEA
The report also includes profiles and historical results for some of the leading companies in the radiopharmaceutical market, with a focus on the radiopharmaceutical segment of these companies’ operations.
Leading companies and the potential for market growth Overall world revenue for radiopharmaceutical will surpass $5bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Biosimulation Market report helps you In summary, our 234-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the Biosimulation market and 4 different segmentations, with forecasts for 6 Applications, 11 Radioisotopes, 2 Sources and 4 End Users – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 21 of the leading national markets – US, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Poland, Russia, Japan, China, India, Australia & New Zealand, ASEAN, GCC, South Africa, Northern African Countries • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market – including company profiles and forecasts for 9 companies’ biosimulation segment revenues to 2027
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.
Get our report today The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Introduction 1.2 Why You Should Read This Report 1.3 Key Questions Answered by This Analytical Report 1.4 Who is This Report For? 1.5 Methodology 1.6 Frequently Asked Questions (FAQ) 1.7 Associated Visiongain Reports 1.8 About Visiongain
2. Radiopharmaceutical Market Overview 2.1 Introduction 2.1.1 Market Definition 2.1.2 Market Taxonomy 2.2 Global Radiopharmaceutical Market Size and Forecast 2.3 Market Dynamics 2.3.1 Global Radiopharmaceutical Market: Drivers 2.3.1.1 Evolution towards Centralized Pharmacies 2.3.1.2 Increasing Number of PET and SPECT Scanners Globally 2.3.1.3 Minimizing the Dose in Paediatric Nuclear Imaging 2.3.1.4 Consolidation of Supply Chain 2.3.1.5 Growing Interest of Investors of Conventional Pharmaceutical Industries in the Therapeutic Area 2.3.1.6 Russian Supply Initiative for Mo-99 2.3.1.7 Increasing Domestic Radiopharmaceutical Production 2.3.1.8 Rising Incidence of Cancer and Cardiovascular Diseases 2.3.1.9 Diagnostics Remain a Key Focus of Radiopharmaceuticals Companies 2.3.1.10 Advancement in Radiotracers 2.3.2 Global Radiopharmaceutical Market: Restraints 2.3.2.1 Price Sensitivity and Lack of Specified Guidelines 2.3.2.2 Shorter Half Life of Radiopharmaceuticals Devices 2.3.2.3 Closing of Ageing Research Reactors Worldwide 2.3.3 Global Radiopharmaceutical Market: Opportunity 2.3.3.1 Alternative Diagnostic Radiopharmaceuticals Solutions 2.3.3.2 Lutetium 177 2.3.4 Global Radiopharmaceutical Market: Trends 2.3.4.1 Increasing focus of Manufacturers towards Diagnostic Tracers 2.3.4.2 Increasing Penetration of Radio-therapeutics 2.3.4.3 Fluoro-deoxy glucose (FDG) 2.3.4.4 Gallium-68 2.3.4.5 Nuclear pharmacies 2.3.4.6 Shortage of molybdenum-99/technetium-99m 2.4 Key Regulations
3. Global Radiopharmaceutical Market Analysis and Forecast, By Application 3.1 Introduction 3.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Application 3.2 Global Radiopharmaceutical Market Size and Forecast, By Application 3.2.1 Oncology Segment 3.2.2 Cardiology Segment 3.2.3 Gastroenterology 3.2.4 Neuroendocrinology 3.2.5 Neurology 3.2.6 Nephrology 3.2.7 Others 3.3 Global Radiopharmaceutical Market Attractiveness Index, By Application
4. Global Radiopharmaceutical Market Analysis and Forecast, By Radioisotope 4.1 Introduction 4.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Radioisotope 4.2 Global Radiopharmaceutical Market Size and Forecast, By Radioisotope 4.2.1 Tec. 99 Segment 4.2.2 F18 Segment 4.2.3 Iodine 131 Segment 4.2.4 Lutetium 177 Segment 4.2.5 Yttrium 90 Segment 4.2.6 Gallium 68 Segment 4.2.7 Gallium 67 Segment 4.2.8 Rubidium 82 Segment 4.2.9 Iodine 123 Segment 4.2.10 Iodine 125 Segment 4.2.11 Indium 111 Segment 4.2.12 Others Segment 4.3 Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope
5. Global Radiopharmaceutical Market Analysis and Forecast, By Source 5.1 Introduction 5.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Source 5.2 Global Radiopharmaceutical Market Size and Forecast, By Source 5.2.1 Cyclotrons Segment 5.2.2 Nuclear Reactors Segment 5.3 Global Radiopharmaceutical Market Attractiveness Index, By Source
6. Global Radiopharmaceutical Market Analysis and Forecast, By End User 6.1 Introduction 6.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By End User 6.2 Global Radiopharmaceutical Market Size and Forecast, By End User 6.2.1 Hospitals Segment 6.2.2 Diagnostic Imaging Centres Segment 6.2.3 Ambulatory Surgical Centres Segment 6.2.4 Cancer Research Institute Segment 6.3 Global Radiopharmaceutical Market Attractiveness Index, By End User
7. Global Radiopharmaceutical Market Analysis and Forecast, By Region 7.1 Introduction 7.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Region 7.2 Global Radiopharmaceutical Market Size and Forecast, By Region 7.2.1 North America 7.2.2 Latin America 7.2.3 Western Europe 7.2.4 Eastern Europe 7.2.5 Asia Pacific 7.2.6 MEA 7.3 Global Radiopharmaceutical Market Attractiveness Index, By Region
8. North America Radiopharmaceutical Market Analysis and Forecast, 2016–2027 8.1 Introduction 8.1.1 North America Radiopharmaceutical Market 8.1.2 North America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 8.2 North America Radiopharmaceutical Market Size and Forecast, By Country 8.2.1 The U.S. Radiopharmaceutical Market 8.2.2 Canada Radiopharmaceutical Market 8.3 North America Radiopharmaceutical Market Size and Forecast, By Application 8.4 North America Radiopharmaceutical Market Size and Forecast, By Radioisotope 8.5 North America Radiopharmaceutical Market Size and Forecast, By Source 8.6 North America Radiopharmaceutical Market Size and Forecast, By End User 8.7 North America Radiopharmaceutical Market Attractiveness Index 8.7.1 North America Radiopharmaceutical Market Attractiveness Index, By Country 8.7.2 North America Radiopharmaceutical Market Attractiveness Index, By Application 8.7.3 North America Radiopharmaceutical Market Attractiveness Index, By Radioisotope 8.7.4 North America Radiopharmaceutical Market Attractiveness Index, By Source 8.7.5 North America Radiopharmaceutical Market Attractiveness Index, By End User
9. Latin America Radiopharmaceutical Market Analysis and Forecast, 2016–2027 9.1 Introduction 9.1.1 Latin America Radiopharmaceutical Market 9.1.2 Latin America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 9.2 Latin America Radiopharmaceutical Market Size and Forecast, By Country 9.2.1 Brazil Radiopharmaceutical Market 9.2.2 Mexico Radiopharmaceutical Market 9.2.3 Rest of Latin America Radiopharmaceutical Market 9.3 Latin America Radiopharmaceutical Market Size and Forecast, By Application 9.4 Latin America Radiopharmaceutical Market Size and Forecast, By Radioisotope 9.5 Latin America Radiopharmaceutical Market Size and Forecast, By Source 9.6 Latin America Radiopharmaceutical Market Size and Forecast, By End User 9.7 Latin America Radiopharmaceutical Market Attractiveness Index 9.7.1 Latin America Radiopharmaceutical Market Attractiveness Index, By Country 9.7.2 Latin America Radiopharmaceutical Market Attractiveness Index, By Application 9.7.3 Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope 9.7.4 Latin America Radiopharmaceutical Market Attractiveness Index, By Source 9.7.5 Latin America Radiopharmaceutical Market Attractiveness Index, By End User
10. Western Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027 10.1 Introduction 10.1.1 Western Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 10.2 Western Europe Radiopharmaceutical Market Size and Forecast, By Country 10.2.1 U.K. Radiopharmaceutical Market 10.2.2 France Radiopharmaceutical Market 10.2.3 Germany Radiopharmaceutical Market 10.2.4 Italy Radiopharmaceutical Market 10.2.5 Spain Radiopharmaceutical Market 10.2.6 Nordic Radiopharmaceutical Market 10.2.7 Benelux Radiopharmaceutical Market 10.2.8 Rest of Western Europe Radiopharmaceutical Market 10.3 Western Europe Radiopharmaceutical Market Size and Forecast, By Application 10.4 Western Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope 10.5 Western Europe Radiopharmaceutical Market Size and Forecast, By Source 10.6 Western Europe Radiopharmaceutical Market Size and Forecast, By End User 10.7 Western Europe Radiopharmaceutical Market Attractiveness Index 10.7.1 Western Europe Radiopharmaceutical Market Attractiveness Index, By Country 10.7.2 Western Europe Radiopharmaceutical Market Attractiveness Index, By Application 10.7.3 Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope 10.7.4 Western Europe Radiopharmaceutical Market Attractiveness Index, By Source 10.7.5 Western Europe Radiopharmaceutical Market Attractiveness Index, By End User
11. Eastern Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027 11.1 Introduction 11.1.1 Eastern Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 11.2 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Country 11.2.1 Russia Radiopharmaceutical Market 11.2.2 Poland Radiopharmaceutical Market 11.2.3 Rest of Eastern Europe Radiopharmaceutical Market 11.3 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Application 11.4 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope 11.5 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Source 11.6 Eastern Europe Radiopharmaceutical Market Size and Forecast, By End User 11.7 Eastern Europe Radiopharmaceutical Market Attractiveness Index 11.7.1 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country 11.7.2 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application 11.7.3 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope 11.7.4 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source 11.7.5 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User
12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast, 2017–2027 12.1 Introduction 12.1.1 Asia Pacific Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 12.1.2 Asia Pacific Radiopharmaceutical Market, BPS Analysis, By Country 12.2 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Country 12.2.1 China Radiopharmaceutical Market 12.2.2 India Radiopharmaceutical Market 12.2.3 Australia and New Zealand Radiopharmaceutical Market 12.2.4 ASEAN Radiopharmaceutical Market 12.2.5 Japan Radiopharmaceutical Market 12.2.6 Rest of Asia Pacific Radiopharmaceutical Market 12.3 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Application 12.4 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Radioisotope 12.5 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Source 12.6 Asia Pacific Radiopharmaceutical Market Size and Forecast, By End User 12.7 Asia Pacific Radiopharmaceutical Market Attractiveness Index 12.7.1 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country 12.7.2 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application 12.7.3 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope 12.7.4 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source 12.7.5 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User
13. MEA Radiopharmaceutical Market Analysis and Forecast, 2017–2027 13.1 Introduction 13.1.1 MEA Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country 13.2 MEA Radiopharmaceutical Market Size and Forecast, By Country 13.2.1 GCC Countries Radiopharmaceutical Market 13.2.2 South Africa Radiopharmaceutical Market 13.2.3 North Africa Radiopharmaceutical Market 13.2.4 Rest of MEA Radiopharmaceutical Market 13.3 MEA Radiopharmaceutical Market Size and Forecast, By Application 13.4 MEA Radiopharmaceutical Market Size and Forecast, By Radioisotope 13.5 MEA Radiopharmaceutical Market Size and Forecast, By Source 13.6 MEA Radiopharmaceutical Market Size and Forecast, By End User 13.7 MEA Radiopharmaceutical Market Attractiveness Index 13.7.1 MEA Radiopharmaceutical Market Attractiveness Index, By Country 13.7.2 MEA Radiopharmaceutical Market Attractiveness Index, By Application 13.7.3 MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope 13.7.4 MEA Radiopharmaceutical Market Attractiveness Index, By Source 13.7.5 MEA Radiopharmaceutical Market Attractiveness Index, By End User
14. Leading Companies in the Radiopharmaceutical Market 14.1 Competition Dashboard 14.2 Company Share Analysis 14.3 Company Profiles 14.3.1 Siemens AG 14.3.1.1 Basic Information 14.3.1.2 Company Overview 14.3.1.3 Product Offering 14.3.1.4 Financial Statements 14.3.1.5 Company Strategy 14.3.1.6 Key Developments 14.3.2 Eckert & Ziegler 14.3.2.1 Basic Information 14.3.2.2 Company Overview 14.3.2.3 Product Offering 14.3.2.4 Financial Statements 14.3.2.5 Key Developments 14.3.2.6 Company Strategy 14.3.3 Lantheus Medical Imaging, Inc. 14.3.3.1 Basic Information 14.3.3.2 Company Overview 14.3.3.3 Product Offering 14.3.3.4 Financial Statements 14.3.3.5 Key Developments 14.3.3.6 Company Strategy 14.3.4 Cardinal Health, Inc. 14.3.4.1 Basic Information 14.3.4.2 Company Overview 14.3.4.3 Product Offering 14.3.4.4 Financial Statements 14.3.4.5 Key Developments 14.3.4.6 Company Strategy 14.3.5 Bayer AG 14.3.5.1 Basic Information 14.3.5.2 Company Overview 14.3.5.3 Product Offering 14.3.5.4 Financial Statements 14.3.5.5 Key Developments 14.3.5.6 Company Strategy 14.3.6 Bracco Imaging S.P.A 14.3.6.1 Basic Information 14.3.6.2 Company Overview 14.3.6.3 Product Offering 14.3.6.4 Key Developments 14.3.6.5 Company Strategy 14.3.7 Nordion Inc. 14.3.7.1 Basic Information 14.3.7.2 Company Overview 14.3.7.3 Product Offering 14.3.7.4 Key Developments 14.3.7.5 Company Strategy 14.3.8 Advanced Accelerator Applications S.A. 14.3.8.1 Basic Information 14.3.8.2 Company Overview 14.3.8.3 Product Offering 14.3.8.4 Financial Statements 14.3.8.5 Key Developments 14.3.8.6 Company Strategy 14.3.9 Mallinckrodt PLC 14.3.9.1 Basic Information 14.3.9.2 Company Overview 14.3.9.3 Product Offering 14.3.9.4 Financial Statements 14.3.9.5 Key Developments 14.4 Other Companies of Interest in the Radiopharmaceutical Market
15. Conclusion
16. Glossary
Visiongain Report Sales Order Form Associated Visiongain Reports Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 2.1 Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2015–2027 Figure 3.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027 Figure 3.2: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027 Figure 3.4: Global Oncology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.5: Global Cardiology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.6: Global Gastroenterology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Segment, 2014–2027 Figure 3.7: Global Neuroendocrinology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.8: Global Neurology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.9: Global Nephrology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.10: Global Other Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 3.11: Global Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 4.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Radioisotope Segment, 2015–2027 Figure 4.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Tec. 99 Segment, 2014–2027 Figure 4.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By F18 Segment, 2014–2027 Figure 4.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 131 Segment, 2014–2027 Figure 4.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Lutetium 177 Segment, 2014–2027 Figure 4.6: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Yttrium 90 Segment, 2014–2027 Figure 4.7: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 68 Segment, 2014–2027 Figure 4.8: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 67 Segment, 2014–2027 Figure 4.9: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rubidium 82 Segment, 2014–2027 Figure 4.10: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 123 Segment, 2014–2027 Figure 4.11: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 125 Segment, 2014–2027 Figure 4.12: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Indium 111 Segment, 2014–2027 Figure 4.13: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Others Segment, 2014–2027 Figure 4.14: Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 5.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Source Segment, 2015–2027 Figure 5.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cyclotrons Segment, 2014–2027 Figure 5.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Nuclear Reactors Segment, 2014–2027 Figure 5.4: Global Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 6.1: Global Radiopharmaceutical Market AGR (%) Comparison, By End User Segment, 2015–2027 Figure 6.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Hospitals Segment, 2014–2027 Figure 6.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Diagnostic Imaging Centres Segment, 2014–2027 Figure 6.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Ambulatory Surgical Centres Segment, 2014–2027 Figure 6.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cancer Research Institute Segment, 2014–2027 Figure 6.6: Global Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 7.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Region, 2015–2027 Figure 7.2: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.3: Latin American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.4: Western European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.5: Eastern European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.6: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.7: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 7.8: Global Radiopharmaceutical Market Attractiveness Index, By Region, 2017–2027 Figure 8.1: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 8.2: North American Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 8.3: US Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 8.4: Canadian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 8.5: North American Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 8.6: North American Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 8.7: North American Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 8.8: North American Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 8.9: North American Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 9.1: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 9.2: Latin America Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 9.3: Brazilian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 9.4: Mexican Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 9.5: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rest of Latin America, 2014–2027 Figure 9.6: Latin America Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 9.7: Latin America Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 9.8: Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 9.9: Latin America Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 9.10: Latin America Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 10.1: Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.2: Western Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 10.3: UK Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.4: French Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.5: German Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.6: Italian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.7: Spanish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.8: Nordic Radiopharmaceutical Market Value (US$m) Forecast and AGR (%),2014–2027 Figure 10.9: Benelux Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.10: Rest of Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 10.11: Western Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 10.12: Western Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 10.13: Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 10.14: Western Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 10.15: Western Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 11.1: Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 11.2: Eastern Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 11.3: Russian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 11.4: Polish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 11.5: Rest of Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 11.6: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 11.7: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 11.8: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 11.9: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 11.10: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 12.1 Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.2: Asia Pacific Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 12.3: Chinese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.4: Indian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.5: Australia and New Zealand Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.6: ASEAN Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.7: Japanese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.8: Rest of Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 12.9: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 12.10: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 12.11: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 12.12: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 12.13: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 13.1: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 13.2: MEA Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027 Figure 13.3: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By GCC Countries, 2014–2027 Figure 13.4: South African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 13.5: North African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 13.6: Rest of MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027 Figure 13.7: MEA Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027 Figure 13.8: MEA Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027 Figure 13.9: MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027 Figure 13.10: MEA Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027 Figure 13.11: MEA Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027 Figure 14.1: Leading Radiopharmaceutical Companies, By Market Share (%), 2016 Figure 14.2: Siemens Segment Percentage Split (2016) Figure 14.3: Siemens Geographical Percentage Split (2016) Figure 14.4: Eckert & Ziegler Segment Percentage Split Figure 14.5: Eckert & Ziegler Geographic Percentage Split Figure 14.6: Lantheus Medical Imaging, Inc. Segment Percentage Split Figure 14.7: Lantheus Medical Imaging, Inc. Geographical Percentage Split Figure 14.8: Cardinal Health, Inc. Segment Percentage Split Figure 14.9: Cardinal Health, Inc. Geographical Percentage Split Figure 14.10: Bayer AG Segment Percentage Split Figure 14.11: Bayer AG Segment Geographical Percentage Split Figure 14.12: Advanced Accelerator Applications S.A., Segment Percentage Split Figure 14.13: Advanced Accelerator Applications S.A., Geographical Percentage Split Figure 14.14: Mallinckrodt PLC Segment Percentage Split Figure 14.15: Mallinckrodt PLC Geographical Percentage Split Figure 15.1 Radiopharmaceutical Market Drivers and Restraints
List of Tables Table 2.1 Global Radiopharmaceutical Market Segmentation Table 3.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016–2027 Table 3.2 Global Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 5.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016–2027 Table 6.1: Global Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 7.1: Global Radiopharmaceutical Market Forecast, By Region ($m, AGR%, CAGR%) 2016-2027 Table 8.1: North American Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 8.3: North American Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 8.4: North American Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 9.1: Latin America Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 9.2: Latin America Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 9.4: Latin America Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 9.5: Latin America Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2017 Table 10.1: Western Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 10.2: Western Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 10.4: Western Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 10.5: Western Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 11.1: Eastern Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 11.2: Eastern Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 11.4: Eastern Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 11.5: Eastern Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 12.1: Asia Pacific Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 12.2: Asia Pacific Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 12.4: Asia Pacific Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 12.5: Asia Pacific Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 13.1: MEA Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027 Table 13.2: MEA Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027 Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued) Table 13.4: MEA Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027 Table 13.5: MEA Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027 Table 14.1: Radiopharmaceutical Market Competitive Overview Table 14.2: Siemens AG Overview, 2016 Table 14.3: Siemens AG Financial Overview, 2014-2016 Table 14.4: Siemens Recent Developments Table 14.5: Eckert & Ziegler Overview, 2016 Table 14.7: Eckert & Ziegler Recent Developments Table 14.8: Lantheus Medical Imaging, Inc., Overview, 2016 Table 14.9 Lantheus Medical Imaging, Inc., Financial Overview 2013-2015 Table 14.10: Lantheus Medical Imaging, Inc., Recent Developments Table 14.13: Cardinal Health Inc. Recent Developments Table 14.14: Bayer AG, Overview, 2016 Table 14.15: Bayer AG, Financial Overview, 2014-2016 Table 14.16: Bayer AG Recent Developments Table 14.17: Bracco Imaging S.P.A, Overview, 2016 Table 14.18: Bracco Imaging S.P.A, Recent Developments Table 14.19: Nordion Inc., Overview, 2016 Table 14.20: Siemens Recent Developments Table 14.21: Advanced Accelerator Applications S.A., Overview, 2016 Table 14.22: Advanced Accelerator Applications S.A., Financial Overview, 2013-2015 Table 14.23: Advanced Accelerator Applications S.A. Recent Developments Table 14.24: Mallinckrodt PLC, Overview, 2016 Table 14.25: Mallinckrodt PLC, Overview, 2016 Table 14.26: Siemens Recent Developments Table 14.27: Other Companies of Interest in the Radiopharmaceutical Market
ABX GmbH Actinium Pharmaceuticals, Inc. Advanced accelerator applications S.A Advion, Inc. Alliance Medical ANMI Avid Radiopharmaceuticals Bayer Biodex Biomedica Life Sciences S.A Bracco Imaging S.P.A BV Cyclotron VU Cardinal Health, Inc. Clarity Pharmaceuticals Comecer Group Coquí RadioPharmaceuticals, Corp. Coquí RadioPharmaceuticals, Corp. Cyclomedical Cyclopharm Danish International DuChemBio Co., Ltd Eckert & Ziegler Eczacıbaşı-Monrol Nuclear Products Eli Lilly and Company ELYSIA s.a. Euromechanics saveRay GmbH FUJIFILM Holdings Corporation GIPHARMA IDB Holland BV Immunomedics, Inc. Ion Beam Applications IQ Medical Services Isologic Innovative Radiopharmaceuticals Isorad Ltd IsoTherapeutics Group, LLC Jubilant Pharma. LLC Lantheus Medical Imaging, Inc. M.G.P. M.G.P. spol. s r. o. Medi-Radiopharma Modus Medical Devices Inc. MR Solutions Navidea Biopharmaceuticals, Inc. Nordion, Inc OctreoPharm Sciences GmbH Optimized Radiochemical Applications PARS ISOTOPE Co. PET Pharm Biotech Co., Ltd Piramal Group Rapidscan Pharma Solutions ROTOP Pharmaka GmbH RPH Group SANLAR Group SCETI K.K Shertech Pharmacy Siemens AG Siemens Healthineers Sirtex Medical Europe GmbH SK CAPITAL St Mary’s Pharmaceutical Synektik Group Tema Sinergie The Voxel S.A. Toshiba Medical Systems Corporation Tracer Pharma ApS TRASIS S.A. Triad Isotopes, Inc. Zevacor Molecular Zevacor Pharma, Inc.
List of Organizations European Medicines Agency Food and Drug Administration (FDA) Medicines and Healthcare Products Regulatory Agency (MHRA) Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) Organization for Economic Co-operation and Development (OECD) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for The Global Radiopharmaceutical Market Forecast 2017-2027
Download sample pages
Complete the form below to download your free sample pages for The Global Radiopharmaceutical Market Forecast 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
